A Phase I, International, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of BL0175 Injection Compared With a Single Dose of Fulvestrant Injection in Postmenopausal Women
Latest Information Update: 03 Feb 2026
At a glance
- Drugs Fulvestrant (Primary)
- Indications Menopause
- Focus Adverse reactions
- Sponsors Shanghai Best-Link Biosciences
Most Recent Events
- 03 Feb 2026 New trial record